Difference between revisions of "Xu X, et al, (2020), cited as Ref 66 in DOI:10.1007/s11886-020-01292-3 (Q10575)"
Jump to navigation
Jump to search
(Created claim: Sixth Author string (P154): Fu B, #quickstatements; #temporary_batch_1592503575618) |
(Added link to [sliswiki]: Xu X, et al, (2020), cited as Ref 66 in DOI:10.1007/s11886-020-01292-3, #quickstatements; #temporary_batch_1592946843269) |
||||||||||||||
| (One intermediate revision by the same user not shown) | |||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2020
| ||||||||||||||
| Property / Publication Date: 2020 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| links / sliswiki / name | links / sliswiki / name | ||||||||||||||
| + | |||||||||||||||
Latest revision as of 21:15, 23 June 2020
Cited in: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response" Research article published in Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Xu X, et al, (2020), cited as Ref 66 in DOI:10.1007/s11886-020-01292-3
|
Cited in: "Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response" Research article published in Curr Cardiol Rep; 2020 04 21 ; 22 (5) 32.
|
Statements
Q10356 (Deleted Item)
0 references
Effective treatment of severe COVID-19 patients with Tocilizumab (English)
0 references
Xu X
0 references
Han M
0 references
Li T
0 references
Sun W
0 references
Wang D
0 references
Fu B
0 references
2020
0 references
